Berkshire Hathaway has agreed to buy OxyChem, the chemical subsidiary, in an all-cash purchase of $9.7 billion. Occidental Petroleum’s financial and strategic link between the two companies is loaded with debt from prior major acquisitions like Anadarko and CrownRock. Occidental intends to use $6.5 billion of the proceeds to reduce its net debt under the $15 billion level.
The agreement comes after years of financial collaboration; Berkshire already owns about 29 to 30% of Occidental’s equity and has previously supported its proposal to buy Anadarko . $10 billion capital infusion in 2019. From Berkshire’s point of view, OxyChem balances its current chemical resources (such as Lubrizol) and offers a stable operating unit with an estimated pre-tax income of around $800 million. suggesting an investment return of about 6-7 %.
Also Read: Trump Plans New Tariffs Targeting European Pharma and Heavy Trucks
Still, some experts warn that the transaction moves the needle only slightly in the setting of Berkshire’s enormous cash trove, nearly $344 billion. Many see this purchase as Buffett’s last big play as he is expected to resign as CEO by year’s end. Under Greg Abel , Buffett’s chosen successor, the deal is being guided, therefore strengthening Abel’s rising leadership. Observers view this as a test of Abel’s future aggressiveness in using Berkshire’s cash.
For his part, Warren Buffett is scheduled to stay chairman and will likely keep sway over future capital distribution. The OxyChem transaction’s timing and scope demonstrate a rare concordance of heritage and opportunity: a mature business passing off a high-profile project precisely as its creator gets ready to leave the front line.
How Berkshire combines OxyChem’s operations while maintaining margins in light of the cyclic nature of chemicals will be critical to success. Protection for Berkshire, Occidental keeps all environmental responsibilities connected with the purchased unit. Occidental’s capacity to significantly lower its debt and reinstate shareholder returns through buybacks is therefore very reliant on macro commodity prices.